Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial.

Grimnes G, Joakimsen R, Figenschau Y, Torjesen PA, Almås B, Jorde R.

Osteoporos Int. 2012 Jan;23(1):201-11. doi: 10.1007/s00198-011-1752-5. Epub 2011 Sep 10.

PMID:
21909730
2.

Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women.

Macdonald HM, Wood AD, Aucott LS, Black AJ, Fraser WD, Mavroeidi A, Reid DM, Secombes KR, Simpson WG, Thies F.

J Bone Miner Res. 2013 Oct;28(10):2202-13. doi: 10.1002/jbmr.1959.

3.

Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.

Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.

Osteoporos Int. 2015 Sep;26(9):2365-74. doi: 10.1007/s00198-015-3141-y. Epub 2015 May 1. Erratum in: Osteoporos Int. 2015 Nov;26(11):2719-20.

4.

The impact of dietary calcium intake and vitamin D status on the effects of zoledronate.

Bourke S, Bolland MJ, Grey A, Horne AM, Wattie DJ, Wong S, Gamble GD, Reid IR.

Osteoporos Int. 2013 Jan;24(1):349-54. doi: 10.1007/s00198-012-2117-4. Epub 2012 Aug 15.

PMID:
22893357
5.

The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.

Zhu HM, Qin L, Garnero P, Genant HK, Zhang G, Dai K, Yao X, Gu G, Hao Y, Li Z, Zhao Y, Li W, Yang J, Zhao X, Shi D, Fuerst T, Lu Y, Li H, Zhang X, Li C, Zhao J, Wu Q, Zhao SJ.

Osteoporos Int. 2012 Apr;23(4):1317-27. doi: 10.1007/s00198-011-1577-2. Epub 2011 Apr 20.

PMID:
21505910
6.

Treatment of Vitamin D Insufficiency in Postmenopausal Women: A Randomized Clinical Trial.

Hansen KE, Johnson RE, Chambers KR, Johnson MG, Lemon CC, Vo TN, Marvdashti S.

JAMA Intern Med. 2015 Oct;175(10):1612-21. doi: 10.1001/jamainternmed.2015.3874.

7.

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.

Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.

Menopause. 2013 Jan;20(1):72-8. doi: 10.1097/gme.0b013e31825fe2e8.

PMID:
22968256
8.

Dose-response study of denosumab on bone mineral density and bone turnover markers in Japanese postmenopausal women with osteoporosis.

Nakamura T, Matsumoto T, Sugimoto T, Shiraki M.

Osteoporos Int. 2012 Mar;23(3):1131-40. doi: 10.1007/s00198-011-1786-8. Epub 2011 Sep 17.

PMID:
21927920
9.

Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.

Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.

Clin Rheumatol. 2005 Jun;24(3):232-8. Epub 2005 Jan 13.

PMID:
15647969
10.

Supplementation with oral vitamin D3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial.

Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ.

J Bone Miner Res. 2004 Aug;19(8):1221-30. Epub 2004 May 24.

11.

Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomized controlled trial.

Cheung AM, Tile L, Lee Y, Tomlinson G, Hawker G, Scher J, Hu H, Vieth R, Thompson L, Jamal S, Josse R.

PLoS Med. 2008 Oct 14;5(10):e196. doi: 10.1371/journal.pmed.0050196. Erratum in: PLoS Med. 2008 Dec;5(12):e247.

12.

Effectiveness and safety of vitamin D in relation to bone health.

Cranney A, Horsley T, O'Donnell S, Weiler H, Puil L, Ooi D, Atkinson S, Ward L, Moher D, Hanley D, Fang M, Yazdi F, Garritty C, Sampson M, Barrowman N, Tsertsvadze A, Mamaladze V.

Evid Rep Technol Assess (Full Rep). 2007 Aug;(158):1-235. Review.

13.

No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year.

Jorde R, Sneve M, Torjesen PA, Figenschau Y, Hansen JB, Grimnes G.

Nutr J. 2010 Jan 7;9:1. doi: 10.1186/1475-2891-9-1.

14.

A randomized controlled trial of vitamin D3 supplementation in African American women.

Aloia JF, Talwar SA, Pollack S, Yeh J.

Arch Intern Med. 2005 Jul 25;165(14):1618-23.

15.

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.

Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.

Clin Ther. 2007 Sep;29(9):1937-49.

PMID:
18035193
16.

Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.

Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.

Osteoporos Int. 2006;17(5):716-23. Epub 2006 Feb 3.

PMID:
16463007
17.

Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.

Roux C, Binkley N, Boonen S, Kiel DP, Ralston SH, Reginster JY, Pong A, Rosenberg E, Santora A; FOCUS-D Investigators.

Calcif Tissue Int. 2014 Feb;94(2):153-7. doi: 10.1007/s00223-013-9763-1. Epub 2013 Aug 4. Erratum in: Calcif Tissue Int. 2014 Feb;94(2):158. Regnister, Jean-Yves [corrected to Reginster, Jean-Yves].

PMID:
23912950
18.

A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.

Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C, Buben CE, Gilligan JP, Krause DS; Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) Investigators.

J Bone Miner Res. 2012 Aug;27(8):1821-9. doi: 10.1002/jbmr.1602.

19.

The effect of season and vitamin D supplementation on bone mineral density in healthy women: a double-masked crossover study.

Patel R, Collins D, Bullock S, Swaminathan R, Blake GM, Fogelman I.

Osteoporos Int. 2001;12(4):319-25.

PMID:
11420782
20.

Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.

Kendler DL, Palacios S, Cox DA, Stock J, Alam J, Dowsett SA, Zanchetta J.

Osteoporos Int. 2012 Mar;23(3):1091-101. doi: 10.1007/s00198-011-1587-0. Epub 2011 Mar 4.

PMID:
21374068

Supplemental Content

Support Center